3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Neoplasms
4
Venous Thrombosis
2
Venous Thromboembolism
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Thrombosis
1
Thromboembolism
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Dyskinesias
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
13
Oxaliplatin
9
Capecitabine
6
lenvatinib
5
apatinib
5
Cisplatin
5
tislelizumab
4
Surgical Procedures, Operative
4
Radiofrequency Ablation
4
Neoadjuvant Therapy
4
Fluorouracil
4
toripalimab
3
sintilimab
3
Radiotherapy
3
Leucovorin
3
Irinotecan
3
regorafenib
2
pembrolizumab
2
durvalumab
2
camrelizumab
2
Stents
2
Photochemotherapy
2
Immunotherapy
2
Hepatectomy
2
Folfox protocol
2
Everolimus
2
Drug Therapy
2
Cholangiopancreatography, Endoscopic Retrograde
2
Blood Specimen Collection
2
1-phenyl-3,3-dimethyltriazene
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Cholangiocarcinoma
×
Rivaroxaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled